Bristol-Myers Squibb
-0.3 %
12.97 %
Yet to be announced
Company Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma.
Revenue Sources
PassAfter reviewing Bristol-Myers Squibb's product portfolio and revenue sources, their income primarily comes from the development and sale of pharmaceutical products. These products and services are considered halal as they provide medical treatments that improve human health and well-being. There is no evidence of significant revenue from prohibited sources such as alcohol, gambling, or other haram activities.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| March 31, 2025 | $11.2b | $7.89b | - | - | 0.00% | 0.00% |
| Dec. 31, 2024 | $12.34b | $11.86b | - | - | 0.00% | 0.00% |
| Sept. 30, 2024 | $11.89b | $9.98b | - | - | 0.00% | 0.00% |
| June 30, 2024 | $12.2b | $10.64b | - | - | 0.00% | 0.00% |
Based on the financial data from the last four quarters, Bristol-Myers Squibb reported zero interest income and zero interest expense across all periods. This indicates that interest-based income and expenses are not material to the company's operations. The company's primary revenue comes from its core pharmaceutical business.
Operational Ethics
PassBristol-Myers Squibb operates globally but maintains stringent ethical standards in its operations. While the company does business in various markets, there is no evidence of material ongoing collaboration with entities involved in human rights violations. The company has established compliance programs and ethical guidelines that govern its international operations.
Comments